Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington's disease mouse model

• Main Authors: Yu Jin Hwang (Author), Seung Jae Hyeon (Author), Younghee Kim (Author), Sungsu Lim (Author), Min Young Lee (Author), Jieun Kim (Author), Ashwini M. Londhe (Author), Lizaveta Gotina (Author), Yunha Kim (Author), Ae Nim Pae (Author), Yong Seo Cho (Author), Jihye Seong (Author), Hyemyung Seo (Author), Yun Kyung Kim (Author), Hyunah Choo (Author), Hoon Ryu (Author), Sun-Joon Min (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The present study describes evaluation of epigenetic regulation by a small molecule as the therapeutic potential for treatment of Huntington's disease (HD). We identified 5-allyloxy-2-(pyrrolidin-1-yl)quinoline (APQ) as a novel SETDB1/ESET inhibitor using a combined in silico and in vitro cell...